Experience

Aescape Acquires Exclusive Rights to Tom Brady’s Science-Backed Longevity Protocols

September 23, 2025

Cooley advised Aescape, the leader in artificial intelligence-powered recovery technology, on its acquisition of the exclusive rights to Tom Brady’s recovery and longevity protocols.

Read more

Related contacts

Mike Lincoln
Vice Chair, Reston
Danielle Gershowitz
Partner, New York
Alex Abelson
Associate, New York
Adam Chase
Partner, Washington, DC
Nyron J. Persaud
Partner, New York
Rhea George
Associate, New York
Stephanie Gentile
Partner, New York
Joshua Holleman
Partner, Washington, DC
Wesley Dietrich
Associate, Washington, DC
Caolinn Mejza
Associate, New York
Talya Whyte
Associate, New York

Related Practices & Industries

Cerberus Ventures Leads Syntis Bio’s $38 Million Financing

July 1, 2025

Cooley advised Cerberus Ventures, a venture fund established in 2023 to invest in early-stage companies in sectors important to government and innovators, as lead investor in Syntis Bio’s $38 million financing. Partners Matthew Bartus, Marc Recht and Christophe Beauduin led the Cooley team advising Cerberus Ventures.

Related contacts

Matthew Bartus
Partner, San Francisco
Marc Recht
Partner, Boston
Christophe Beauduin
Partner, New York
Andrew Leonard
Associate, Washington, DC
Alex Abelson
Associate, New York
Dr. Marcelo Pomeranz
Associate, San Diego
Michael Fernando
Associate, London

Related Practices & Industries

Odeko Closes $126 Million Series E

March 4, 2025

Cooley advised Odeko, a mobile ordering and supply chain management software for coffee shops and cafés, on its $126 million Series E financing round. Lawyers Tamim Bazzi, Alex Abelson, Christopher Nickas and Sophie Kraff led the Cooley team advising Odeko.

Related contacts

Tamim Bazzi
Partner, New York
Alex Abelson
Associate, New York
Sophie Kraff
Associate, New York
Greg Reith
Associate, Washington, DC

Related Practices & Industries

Windward Bio Closes $200 Million Series A

January 10, 2025

Cooley advised Windward Bio, a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases, on its $200 million Series A financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Windward Bio.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York

Related Practices & Industries

Questa Capital Leads OSSIO’s $27.6 Million Financing

December 2, 2024

Cooley advised Questa Capital, a venture growth equity firm focused on later-stage companies across healthcare, as lead investor in the $27.6 million financing round of OSSIO. OSSIO is a medical device company focused on evolving orthopedic surgery with bio-integrative fixation technology. Partner Brandon Fenn led the Cooley team advising Questa Capital.

Related contacts

Brandon W. Fenn
Partner, New York
Xander Lee
Partner, Santa Monica
Noah Pittard
Partner, Colorado
Alex Abelson
Associate, New York

Related Practices & Industries

View more

Admissions and credentials

New York

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.